Connecta Therapeutics

Spain - BarcelonaBiotechnology1 H-1B visas (FY2023)

Focus: Connecta Therapeutics is a Barcelona-based biotech focused on small molecule discovery for rare diseases, currently in early-stage development with a single Phase 1 program.

Rare Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Connecta Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Connecta Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Any

Fragile X Syndrome (FXS)

N/A

Clinical Trials (1)

NCT06957054Neural Biomarkers in Fragile X Syndrome

N/A

Help build intelligence for Connecta Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to shape early-stage drug discovery at ground level in an emerging biotech with rare disease focus
Location in Barcelona provides access to European biotech talent and networks
Work on unmet medical needs in Fragile X Syndrome, a rare genetic disorder with limited treatment options

Watch Out For

No active job openings currently listed, indicating minimal near-term hiring
Pre-revenue stage with unknown funding and financial runway creates significant stability risk
Single Phase 1 program represents very early clinical validation with lengthy path to commercialization

Generated by Claude from Connecta Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

CTH120

Fragile X Syndrome

Phase 1

Clinical Trials (1)

NCT06480968CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food Interaction

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Rare Diseases

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Rare Diseases

2 pipeline

Marketed

Pipeline

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub